We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bacterium Actively Drives CRC Tumor Growth

By LabMedica International staff writers
Posted on 27 Jul 2017
Colorectal cancer (CRC) is a leading cause of cancer-related death. More...
The recognition that microbial agents can contribute to the development of CRC raises hope for improving CRC diagnosis and treatment by incorporating both microbial and patient characteristics into clinical strategies.

It has been known for some time that people infected with the Streptococcus gallolyticus subspecies gallolyticus (Sgg) are more likely to have colorectal cancer (CRC), and is the second most common cause of cancer in women. However, it was unknown whether Sgg actively promotes CRC or whether it simply grows comfortably in the environment provided by CRC tumor cells.

Scientists at Texas A&M Health Science Center (Houston, TX, USA) and colleagues performed several studies using cultured human colorectal cells, mice with CRC, and tissue from human tumors. They used various techniques including using cultured bacterial cell lines, human colon cancer cell lines, cell proliferation assays, adherence and internalization assays, Western blot assays. They also performed quantitative reverse transcription polymerase chain reaction (RT-qPCR) to compare relative expression of cyclin D1 and cytokines in a Viia 7 Real Time PCR System. Flow cytometry analysis of samples was done using a LSRII flow cytometer.

The investigators demonstrated that Sgg promotes human colon cancer cell proliferation in a manner that depends on cell context, bacterial growth phase and direct contact between bacteria and colon cancer cells. In addition, they observed increased level of β-catenin, c-Myc and proliferating cell nuclear antigen (PCNA) in colon cancer cells following incubation with Sgg. The team tested tumor samples from people with colon cancer, they found 74% had Sgg bacteria in them, and 26% had very high levels of it. They also showed that Sgg is present in the majority of CRC patients and is preferentially associated with tumor compared to normal tissues obtained from CRC patients.

The authors concluded that overall, their findings strongly suggest that Sgg plays an active role in CRC development in humans. In the future, the precise mechanisms of its tumor-promoting activity could potentially be exploited to develop new strategies to diagnose, prevent, and treat CRC. The study was published on July 13, 2017, in the journal Public Library of Science Pathogens.

Related Links:
Texas A&M Health Science Center


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.